E
Eric J. Topol
Researcher at Scripps Health
Publications - 1406
Citations - 162373
Eric J. Topol is an academic researcher from Scripps Health. The author has contributed to research in topics: Myocardial infarction & Angioplasty. The author has an hindex of 193, co-authored 1373 publications receiving 151025 citations. Previous affiliations of Eric J. Topol include Loyola University Chicago & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
The prognostic value of creatine kinase elevations extends across the whole spectrum of acute coronary syndromes.
Stefano Savonitto,Christopher B. Granger,Diego Ardissino,Laura H. Gardner,Claudio Cavallini,Marcello Galvani,Filippo Ottani,Harvey D. White,Paul W. Armstrong,E. Magnus Ohman,Karen S. Pieper,Robert M. Califf,Eric J. Topol +12 more
TL;DR: Although high-risk patients with ACS often develop lesser CK elevations, this study demonstrated that even minor enzyme elevations appear to have important and independent prognostic implications.
Journal ArticleDOI
Foundation models for generalist medical artificial intelligence
Michael Moor,O. Banerjee,Zahra F.H. Abad,Harlan M. Krumholz,Jure Leskovec,Eric J. Topol,Pranav Rajpurkar +6 more
TL;DR: Generalist medical AI (GMAI) as mentioned in this paper is a new paradigm for medical AI, which is capable of carrying out a diverse set of tasks using very little or no task-specific labelled data.
Journal ArticleDOI
Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease.
John G. Peterson,Eric J. Topol,Shelley K Sapp,James B. Young,A. Michael Lincoff,Michael S. Lauer +5 more
TL;DR: Combined use of aspirin and ACE inhibitors was associated with increased mortality in GUSTO-I patients and in EPILOG patients, suggesting the possibility of an interaction between aspirin andACE inhibitors among patients with ischemic heart disease.
Journal ArticleDOI
Confronting the issues of patient safety and investigator conflict of interest in an international clinical trial of myocardial reperfusion
Eric J. Topol,Paul W. Armstrong,Frans Van de Werf,Neal S. Kleiman,Kerry L. Lee,Douglas C. Morris,Maarten L. Simoons,Gabriel I. Barbash,Harvey D. White,Robert M. Califf +9 more
TL;DR: The GUSTO trial is a large scale international trial of new myocardial reperfusion strategies and a strategy was developed to provide assurance of patient safety during large scale investigational use of an aggressive thrombolytic regimen to facilitate the design of future large scale randomized trials in cardiovascular medicine.
Journal ArticleDOI
Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction
Robert A. Harrington,David C. Sane,Robert M. Califf,Kristina N. Sigmon,Charles W. Abbottsmith,Richard J. Candela,Kerry L. Lee,Eric J. Topol +7 more
TL;DR: Thrombocytopenia after thrombolytic therapy is a common event and is associated with excess hemorrhage and mortality, and platelet counts should be monitored daily after administration of throm Bolytic Therapy for acute myocardial infarction.